A Phase III randomized, open label study of NiraParib maintenance after Carboplatin and Paclitaxel in optimaLly debUlked advanced HRDpositive high grade ovarian cancer patientS in first line therapy
Trial Number
NCT05460000 (ClinicalTrials.gov Identifier)Contact Person
Status
Pending
Disease Site
Ovarian
Lead Cooperative Group
Participating Groups
BGOG
AGO-AUST
MaNGO